One procedure to replace lifelong blood thinners? new trial tests dual heart fix for stroke survivors

NCT ID NCT06212674

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether a single procedure that combines two heart treatments—pulmonary vein isolation (to correct irregular heartbeat) and left atrial appendage occlusion (to block a clot-prone area)—can prevent future strokes and major bleeding better than standard blood thinners. The trial enrolls 240 adults who recently had a stroke and have atrial fibrillation. Participants are randomly assigned to the combined procedure, the occlusion procedure alone, or continued medication. The goal is to see if the combined approach is at least as effective as medication, with fewer bleeding risks.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Procedure: pulmonary vein isolation (PVI) plus left atrial appendage occluder (LAAO) implantation

What this could lead to

If successful, this combined procedure could offer a one-time treatment to reduce stroke risk and bleeding complications compared to lifelong blood thinners.

What could go wrong

This is a Phase 4 trial with 240 participants, so results are preliminary. The procedure carries risks like bleeding, infection, or device complications, and may not be superior to standard medication.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ISCHEMIC STROKE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

atrial fibrillation ischemic stroke

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Silesian Center for Heart Disease

    RECRUITING

    Zabrze, Upper Silesia, 41-800, Poland

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Upper-Silesian Medical Center

    RECRUITING

    Katowice, Upper Silesia, 40-635, Poland

    Contact

    Contact

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

    Contact

    Contact

    Contact

    Contact